Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Allison Berger"'
Publikováno v:
Leukemialymphoma. 60(12)
With the advent of proteasome inhibitors (bortezomib) and pleiotropic pathway modulators which target cereblon E3 ligase (lenalidomide), the ubiquitin-proteasome system has emerged as a tractable target in non-Hodgkin lymphoma and multiple myeloma. H
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no
Autor:
Fazal Shirazi, Marc L. Hyer, R. Eric Davis, Isere Kuiatse, Hans C. Lee, Vaishali Shinde, Allison Berger, Hua Wang, Junling Zhuang, Sakeena Syed, Zhiqiang Wang, Zuzana Berkova, Robert Z. Orlowski, Richard J. Jones, Nibedita Chattopadhyay, Judy Qiuju Shi, Jie Yu, Stephen Tirrell, Ram Kumar Singh
Publikováno v:
Blood. 133(14)
Three proteasome inhibitors have garnered regulatory approvals in various multiple myeloma settings; but drug resistance is an emerging challenge, prompting interest in blocking upstream components of the ubiquitin-proteasome pathway. One such attrac